In this section
Assorted resources on conditions connected to Cardiology.
Latest information on diseases in Dermatology.
A detailed look at conditions connected to Endocrinology.
Gastroenterology and Hepatology
In-depth material on Gastroenterology and Hepatology.
Assorted resources on conditions connected to Haematology.
Immunology, the immune system and immune-mediated diseases.
A detailed look at conditions connected to Infectious Diseases.
Assorted resources on conditions related to Nephrology.
Neurology (CNS) and Pain
Learning materials and guidelines on Neurology (CNS) and Pain.
A detailed look at conditions connected to Oncology.
Assorted resources on conditions connected to Ophthalmology.
In-depth material on Respiratory conditions.
Latest information on diseases in Rheumatology.
Learning materials and guidelines on Urology.
Gilead Sciences, Inc. announced the FDA has lifted the clinical hold placed on the company’s Investigational New Drug Application (IND) to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP).
Bristol Myers Squibb announced the Phase III CheckMate -901 trial, comparing Opdivo (nivolumab) plus Yervoy (ipilimumab) to standard-of-care chemotherapy as a first-line treatment for patients with untreated unresectable or metastatic urothelial carcinoma, did not meet the primary endpoint of overall survival (OS) in patients whose tumor cells express PD-L1 greater than 1% at final analysis.
Lantheus Holdings, Inc. presented results from a retrospective analysis of quantitative Pylarify (piflufolastat F18) PSMA (prostate specific membrane antigen) scan indices as a response imaging-biomarker to androgen deprivation therapy in veterans with newly diagnosed metastatic prostate cancer.